Ascendis Pharma A/S
F:A71
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Ascendis Pharma A/S
F:A71
|
DK |
|
Uniper SE
F:UN0
|
DE |
|
M
|
Mckesson Corp
XMUN:MCK
|
US |
|
O
|
Ono Pharmaceutical Co Ltd
XMUN:ON4
|
JP |
|
C
|
Comtech Telecommunications Corp
XMUN:CC6
|
US |
|
A
|
Airbus SE
XMUN:AIR
|
NL |
|
C
|
Central Garden & Pet Co
F:GP7
|
US |
|
DRDGOLD Ltd
F:DUBA
|
ZA |
|
P
|
Pilgrims Pride Corp
F:6PP
|
US |
|
E
|
Emmerson Resources Ltd
F:42E
|
AU |
|
P
|
PNC Financial Services Group Inc
XMUN:PNP
|
US |
Wall St Price Targets
A71 Price Targets Summary
Ascendis Pharma A/S
According to Wall Street analysts, the average 1-year price target for
A71 is 243.44 EUR with a low forecast of 209.31 EUR and a high forecast of 291.85 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is A71's stock price target?
Price Target
243.44
EUR
According to Wall Street analysts, the average 1-year price target for
A71 is 243.44 EUR with a low forecast of 209.31 EUR and a high forecast of 291.85 EUR.
What is the Revenue forecast for Ascendis Pharma A/S?
Projected CAGR
23%
Over the last 12 years, the compound annual growth rate for Revenue has been 35%. The projected CAGR for the next 8 years is 23%.